Paul Hastings LLP advised J.P. Morgan Securities LLC as the exclusive placement agent in the transaction. Leap Therapeutics, Inc. (Nasdaq:LPTX) has entered into a securities purchase agreement with...
Leap Therapeutics’ $40 Million Private Placement
Century Therapeutics’ $60 Million Private Placement
Paul Hastings LLP advised BofA Securities as the sole placement agent in the transaction. Century entered into a securities purchase agreement with a select group of...
Evolus’ $50.0 Million Common Stock Offering
Paul Hastings LLP advised Leerink Partners and Stifel as joint bookrunning managers in the offering. Evolus, Inc. (Nasdaq: EOLS) announced the pricing of its underwritten offering...
Kyowa Kirin’s $387 Million Acquisition of Orchard Therapeutics
Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
HOOKIPA Pharma’s $50 Million Public Offering of Common Stock and Convertible Preferred Stock
Goodwin Procter advised HOOKIPA, and Duane Morris advised the underwriters involved in the offering. HOOKIPA Pharma Inc. (Nasdaq: HOOK) announced its underwritten public offering of 22,900,768...
Sarepta Therapeutics’ $1.15 Billion Notes Offering
Goodwin Procter advised the initial purchasers on the deal. Sarepta Therapeutics, Inc. announced its Rule 144A offering of 1.25% Convertible Senior Notes due 2027. The $1.15 billion...